As several clinical trials using GLI1 inhibitors, like GANT61, have a limitation with respect to crossing the blood–brain barrier and causing unwanted adverse effects [41], therefore, PFD may be a potential candidate drug for glioblastoma treatment, especially in combination with TMZ. Here, GLI1 is linked to glioblastoma.